Skip to main content
Medigene AG logo

Medigene AG — Investor Relations & Filings

Ticker · MDG1 ISIN · DE000A40ESG2 LEI · 391200I33JD2DKZGDX06 F Professional, scientific and technical activities
Open in API
Filings indexed 114 across all filing types
Latest filing 2025-04-22 Report Publication Anno…
Country DE Germany
Listing F MDG1

About Medigene AG

https://medigene.com/

Medigene AG is a biotechnology company that develops T-cell receptor (TCR)-guided immunotherapies for the treatment of cancer. The company utilizes its proprietary End-to-End platform to discover and develop optimized 3S (sensitive, specific, safe) TCRs. These TCRs are designed for application across various therapeutic modalities, including TCR-T cell therapies, TCR-T cell engagers, and TCR-natural killer cell therapies, targeting different forms of cancer. A key clinical program is MDG1015, a third-generation TCR-T therapy targeting the NY-ESO-1/LAGE-1a antigen, which is enhanced with a PD1-41BB costimulatory switch protein. As of August 2025, the company is undergoing insolvency proceedings.

Recent filings

Filing Released Lang Actions
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 1,000 characters) that explicitly states it is a 'Hinweis auf Jahresfinanzbericht' (Notice of Annual Financial Report) and provides a link to where the report will be available. It does not contain the actual financial report itself, but rather notifies the public of its upcoming publication. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-04-22 German
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
Report Publication Announcement Classification · 100% confidence The document text is very short (1046 characters) and explicitly states that a financial report ('Jahresfinanzbericht 2024') is being announced for publication on a future date ('31.07.2025') and provides a link where it will be available. This structure—announcing the publication of a report rather than containing the full report content—fits the definition of a Report Publication Announcement (RPA). It is not the full Annual Report (10-K) or Interim Report (IR) itself.
2025-04-22 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Regulatory Filings Classification · 95% confidence The document is a formal announcement ('BEKANNTMACHUNG') from Medigene Immunotherapies GmbH regarding its financial reporting obligations for the fiscal year 2024 (01.01.2024 to 31.12.2024). Specifically, it states that the subsidiary is exempt from certain disclosure requirements of the German Commercial Code (§ 264 Abs. 3 HGB) because it will be included in the consolidated financial statements of the parent company, Medigene AG, due to a control and profit transfer agreement. This document is not the full Annual Report (10-K), nor is it a standard earnings release (ER) or interim report (IR). It is a specific regulatory notification concerning the status of its financial statements and inclusion in group reporting. Since it deals with the status of annual financial reporting and regulatory compliance related to consolidation, it fits best under the general 'Regulatory Filings' category (RNS) as a specific, non-standard disclosure, or potentially as a Governance Information (CGR) if focusing on consolidation structure, but RNS is the most appropriate fallback for specific, non-standard regulatory notices not covered elsewhere. Given the short length and nature as a formal notice about reporting status, RNS is the best fit.
2024-10-16 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Audit Report / Information Classification · 95% confidence The document is a short announcement (1279 characters) from Medigene Immunotherapies GmbH regarding its financial reporting obligations for the fiscal year 2024 (01.01.2024 to 31.12.2024). It explicitly states that the company is exempt from certain disclosure requirements under § 264 Abs. 3 HGB (German Commercial Code) and will be included in the consolidated financial statements of Medigene AG. This is not the full Annual Report (10-K) or a comprehensive Interim Report (IR). Since it is a formal notification about the status of its financial reporting for the year, and it doesn't fit neatly into specific categories like ER, AR, or DIV, it falls best under the general regulatory announcement category, RNS, as it is a formal regulatory disclosure regarding financial status. FY 2024
2024-09-18 German
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.06.2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresfinanzbericht' (Half-Year Financial Report) for Medigene AG covering the period from January 1, 2024, to June 30, 2024. It includes a 'Konzern-Zwischenlagebericht' (Group Interim Management Report), details on financial performance (revenue, R&D expenses, liquidity), and operational updates. This fits the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-08-14 German
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 5,000 characters) that explicitly states it is a 'Pre-announcement of a financial report' and provides a link to where the actual report will be available. Following the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA) rather than the financial report itself.
2024-06-28 German

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.